|Videos|March 13, 2018

Using Apps to Improve the Management of Staphylococcus aureus

Debra Goff, PharmD, FCCP, discusses how the STAB-IT app helps health care providers with real-time point-of-care management of Staphylococcus aureus bacteremia.

Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist at the Ohio State University Wexner Medical Center, explains how apps can be used to improve the management of harmful bacteria. Dr. Goff and colleagues at her institution developed an app called STAB-IT (Staphylococcus aureus bacteremia is terrible) which allows health care providers to access data regarding diagnosis, management, and treatment of Staph aureus bacteremia in real-time at point-of-care. She stresses that this offers an alternative to delivering lectures, that perhaps fits better in the hectic realm of infectious disease. She adds that another benefit of the app is that it can be updated to reflect any needed changes.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.